T
Tamir Shragai
Researcher at Hebrew University of Jerusalem
Publications - 5
Citations - 67
Tamir Shragai is an academic researcher from Hebrew University of Jerusalem. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications receiving 44 citations.
Papers
More filters
Journal ArticleDOI
Anatomical and functional connectivity in the default mode network of post-traumatic stress disorder patients after civilian and military-related trauma.
Inbal Reuveni,Omer Bonne,Ruti Giesser,Tamir Shragai,Gilad Lazarovits,Moshe Isserles,Shaul Schreiber,Atira S. Bick,Netta Levin +8 more
TL;DR: Type of trauma and time from trauma were found to modulate connectivity patterns and anatomical and functional connectivity patterns are related to PTSD symptoms and trauma characteristics influence connectivity beyond clinical symptoms.
Journal ArticleDOI
Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study
Tamir Shragai,Hila Magen,Noa Lavi,Moshe E. Gatt,Svetlana Trestman,Miri Zektser,Chezi Ganzel,Osnat Dolberg Jarchowsky,Tamar Berger,Tamar Tadmor,Merav Leiba,Katrin Hertzog-Tzarfaty,Netanel A. Horowitz,Michael Y. Shapira,David Varssano,Yoav Berger,Shahar Frenkel,Mark Krauthammer,Irit Avivi,Efrat Luttwak,Yael C Cohen +20 more
TL;DR: In a real-world setting, belantamab mafodotin monotherapy showed efficacy comparable with the prospective clinical trials, with a tolerable toxicity profile.
Journal ArticleDOI
COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge
Yotam Bronstein,Roi Gat,S Levi,Yael C Cohen,Efrat Luttwak,Noam Benyamini,Tamir Shragai,Roy Vitkon,Miriam Neaman,Nili Eilaty,Mor Levi,Svetlana Trestman,Chava Perry,Yair Herishanu,Irit Avivi +14 more
TL;DR: Christensen et al. as discussed by the authors reported the clinical outcome of 131 hematologic patients with lymphoproliferative diseases, infected with SARS-CoV-2 during the Omicron surge in Israel, between January and March 2022.
Journal ArticleDOI
A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)
Yael C Cohen,Tamir Shragai,Noa Lavi,Iuliana Vaxman,Evgeni Chubar,Moshe E. Gatt,Chezi Ganzel,Hila Magen,Efrat Luttwak,Noa Lowenton-Spier,Liron Gez-Aaronson,Natan Melamed,Irit Avivi +12 more
TL;DR: The authors in this paper reported the outcomes of a pre-specified interim analysis of the IPoD-790 clinical trial (NCT04790474), an all oral ixazomib (IXA) pomalidomide (POM) dexamethasone (DEX) combination, in Pts with relapsed refractory multiple myeloma (RRMM) previously treated with bortezomib(BTZ) lenalidomides (LEN) and daratumumab (DARA).
Journal ArticleDOI
P-114: Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: a multi-center retrospective study
Tamir Shragai,Hila Magen,Noa Lavi,Moshe E. Gatt,Svetlana Trestman,Miri Zektser,Chezi Ganzel,Osant Jarchowsky,Tamar Berger,Tamar Tadmor,Merav Leiba,Katrin Hertzog-Zarfaty,Netanel A. Horowitz,Michael Shapira,David Varssano,Yoav Berger,Shahar Frenkel,Mark Krauthammer,Irit Avivi,Efrat Luttwak,Yael C Cohen +20 more